As With Invokana and Farxiga, Jardiance Is Subject Of Several Drug Regulatory Agency Investigations About Ketoacidosis And Other Side Effects
Jardiance is part of the Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors class of diabetes drugs, which also includes Invokana and Farxiga.
These new SGLT-2 diabetes medications -- which are distinctive from other diabetes drugs insofar that they make the kidneys extract a significant amount of sugar from the blood to be excreted in urine -- are prescribed to treat Type-2 diabetes.
Unfortunately, over the years Type 2 diabetes has become much more common, in part due to the so-called obesity epidemic here in the US. About 95 percent of the nearly 30 million American adults and children -- which is almost 10 percent of the current US population -- have Type 2 diabetes. And approximately 86 million more Americans have been diagnosed with "pre-diabetes", with most of those individuals likely to develop diabetes in the future.
As such, the financial analysts who focus on the pharmaceutical sector were all abuzz earlier this week as regards an announcement about a new medical study concerning Jardiance.
From an August 20, 2015 Forbes article, "Sweet Victory: Eli Lilly's Jardiance Is First Diabetes Drug To Reduce Heart Attacks And Strokes", by reporter Matthew Herper, we get a sense of that excitement:
A big win for Eli Lilly this morning. Its diabetes drug Jardiance, co-marketed with Boehringer Ingelheim, is the first blood-sugar lowering pill ever to reduce the risk of heart attacks, strokes, and cardiovascular deaths in a big study, according to a press release issued this morning.
Of course, we need to wait to see full details from the study, not just the press release Lilly and Boehringer issued this morning....
And that Forbes article continued with some discussion about the diabetes drugs market share implications of this recent drug company announcement about Jardiance.
We get some additional information about the significance this new Jardiance medical study from this Associated Press (AP) news report, "Diabetes drug may protect against heart attack, stroke":
... [T]he drug's two manufacturers - Eli Lilly and Co. of Indianapolis and German partner Boehringer Ingelheim GmbH - have announced only that a three-year study they conducted showed the drug delayed the time until patients died of cardiovascular disease or suffered a heart attack or stroke.
That brief summary, known as the top-line result, is meant to inform investors promptly that the closely watched study met its main goal, a result likely to affect Eli Lilly's financial prospects and stock price....
Dr. Ananda Basu, a diabetes specialist at the Mayo Clinic, cautioned that it's impossible to predict how patient treatment will be affected until details of the study design, the size of Jardiance's benefits and any side effects are disclosed.
The two drugmakers plan to release detailed findings at [the European Association for the Study of Diabetes on September 17] and simultaneously publish them in a medical journal.
However, despite this glory-moment for Eli Lilly and Boehringer, all is not well for Jardiance as well as the other SGLT-2 inhibitors such as Invokana and Farxiga.
This situation becomes apparent by the titles of these earlier articles:
Accordingly, referring back to the AP news report above, we are anxious to see the September 2015 medical journal article which will have more details about this recent Jardiance study, and possibly some discussion about the side-effects risks associated with Jardiance.